Overview and recent advances in the treatment of neuroblastoma

Sarah B. Whittle, Valeria Smith, Erin Doherty, Sibo Zhao, Scott McCarty, Peter Zage

Research output: Contribution to journalReview article

91 Scopus citations

Abstract

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma. Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.

Original languageEnglish (US)
Pages (from-to)369-386
Number of pages18
JournalExpert Review of Anticancer Therapy
Volume17
Issue number4
DOIs
StatePublished - Apr 3 2017

Keywords

  • ALK
  • INRG
  • MIBG
  • MYCN
  • Neuroblastoma
  • dinutuximab
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Overview and recent advances in the treatment of neuroblastoma'. Together they form a unique fingerprint.

Cite this